Caicun Zhou

20PUBLICATIONS
39CO-AUTHORS
Molecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Apr 21, 2026
Long-Term Efficacy and Safety of Taletrectinib in Patients With <i>ROS1</i>+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study.

|Aug 21, 2025
Reply to: "Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib" and "Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?"

Maurice Pérol, Wei Li, Rose K Lai

|May 30, 2025
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.

Enriqueta Felip, Nasser Altorki, Caicun Zhou

|Apr 03, 2025
Taletrectinib in <i>ROS1</i>+ Non-Small Cell Lung Cancer: TRUST.

Maurice Pérol, Wei Li, Nathan A Pennell

|Dec 05, 2024
CXCR1<sup>+</sup> neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer.

Haowei Wang, Anwen Xiong, Xiaoxia Chen

|Nov 28, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Caicun Zhou, Gongyan Chen, Yunchao Huang

Pageof 4

Frequent Collaborators

3 joint publications

Maurice Pérol

2 joint publications

Feiwu Ran

2 joint publications

Tao Jiang

2 joint publications

Yongqian Shu